Sio Gene Therapies falls as Q2 loss widens

Sio Gene Therapies

12/11/2021 16:59

** Shares of drug developer  SIOX.O  down ~4% at $1.92
    ** Co’s Q2 net loss widens to $21.2 mln, or 29 cents per
share, from nearly $10 mln, or 21 cents per share, a year
earlier  urn:newsml:reuters.com:*:nGNX1h8PfY
    ** Bigger loss mainly due to higher research and development
costs as expenses increased on studies of co’s two drug
candidates, both of which are being developed to treat types of
genetic disorders that gradually destroy nerve cells
    ** Loss also widened due to more personnel-related costs as
workforce increased 
    ** SIOX shares trading below their 50-, 150- and, 200-day
moving average price
    ** Including session, stock has fallen 30.91% YTD 


 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))